HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Halozyme Therapeutics Inc (HALO) is not a strong buy at this moment for a beginner, long-term investor. Despite strong analyst ratings and positive forward guidance, the technical indicators suggest a bearish trend, and the financial performance shows significant net income and EPS decline. The lack of recent news or congress trading data, coupled with hedge funds selling, further reduces confidence in an immediate buy decision.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 39.698, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 63.582, with resistance at 65.217 and support at 61.947.
Analyst ratings are strong, with multiple firms raising price targets and maintaining Buy or Overweight ratings. The company's partnerships and acquisitions are expected to drive growth in 2026.
Hedge funds are aggressively selling, with a 4215.85% increase in selling activity. Financial performance in Q4 2025 shows a significant decline in net income (-203.34% YoY) and EPS (-213.21% YoY). Gross margin also dropped slightly by 3.18%.
In Q4 2025, revenue increased by 51.60% YoY to $451.77M, but net income dropped significantly to -$141.59M, and EPS fell to -1.2. Gross margin decreased to 77.39%.
Analysts are optimistic, with raised price targets ranging from $75 to $94. They highlight strong quarterly results, positive forward guidance, and growth potential from partnerships and acquisitions.
